Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients

Leukemia Research

Volumn 35, Issue 4, 2011, Pages 448-458

  Joha, Sami ^a   Dauphin, Véronique ^a   Leprêtre, Frédéric ^b   Corm, Sélim ^a,c   Nicolini, Franck E ^d   Roumier, Christophe ^a,c   Nibourel, Olivier ^a,c   Grardel, Nathalie ^c   Maguer Satta, Véronique ^e   Idziorek, Thierry ^a   Figeac, Martin ^b   Laï, Jean Luc ^a,c   Quesnel, Bruno ^a,c   Etienne, Gabriel ^f   Guilhot, François ^g   Lippert, Eric ^h   Preudhomme, Claude ^a,c   Roche Lestienne, Catherine ^a,c  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e CENTRE LÉON BÉRARD   (France)

^f INSTITUT BERGONIÉ   (France)

^g POITIERS UNIVERSITY HOSPITAL   (France)

^h HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

CGH array; Chronic myeloid leukaemia; Genomic instability; Imatinib resistance

Indexed keywords

BCR ABL PROTEIN; IMATINIB; T LYMPHOCYTE RECEPTOR;

ARTICLE; CD34+ CELL; CELL POPULATION; CHROMOSOME 12; CHROMOSOME 13; CHROMOSOME 22Q; CHROMOSOME 7; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE DELETION; GENE LOCUS; GENE MUTATION; GENETIC VARIABILITY; GENOME ANALYSIS; HEMATOPOIETIC STEM CELL; HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 79952362376     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.07.012     Document Type: Article

References (27)

1. Perrotti D., Jamieson C., Goldman J., Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010, 120:2254-2264.
2. Goldman J.M., Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003, 349:1451-1464.
3. Melo J.V., Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7:441-453.
4. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
5. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042.
6. Daub H., Specht K., Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004, 3:1001-1010.
7. Khorashad J.S., De Melo V.A., Fiegler H., Gerrard G., Marin D., Apperley J.F., et al. Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis. Leukemia 2008, 22:1806-1807.
8. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., Lai J.L., Philippe N., Facon T., et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100:1014-1018.
9. Koptyra M., Falinski R., Nowicki M.O., Stoklosa T., Majsterek I., Nieborowska-Skorska M., et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode Imatinib resistance. Blood 2006, 108:319-327.
10. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
11. Deluche L., Joha S., Corm S., Daudignon A., Geffroy S., Quief S., et al. Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?. Genes Chromosomes Cancer 2008, 47:1110-1117.
12. Lepretre F., Villenet C., Quief S., Nibourel O., Jacquemin C., Troussard X., et al. Waved aCGH: to smooth or not to smooth. Nucleic Acids Res 2010, 38:e94.
13. Radich J.P. The Biology of CML blast crisis. Hematol Am Soc Hematol Educ Program 2007, 384-391.
14. Hosoya N., Sanada M., Nannya Y., Nakazaki K., Wang L., Hangaishi A., et al. Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization. Genes Chromosomes Cancer 2006, 45:482-494.
15. Brazma D., Grace C., Howard J., Melo J.V., Holyoke T., Apperley J.F., et al. Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. Genes Chromosomes Cancer 2007, 46:1039-1050.
16. Mullighan C.G., Miller C.B., Radtke I., Phillips L.A., Dalton J., Ma J., et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008, 453:110-114.
17. Kuiper R.P., Waanders E., van der Velden V.H., van Reijmersdal S.V., Venkatachalam R., Scheijen B., et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010, 24:1258-1264.
18. Kuiper R.P., Schoenmakers E.F., van Reijmersdal S.V., Hehir-Kwa J.Y., van Kessel A.G., van Leeuwen F.N., et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 2007, 21:1258-1266.
19. Kawamata N., Ogawa S., Zimmermann M., Kato M., Sanada M., Hemminki K., et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 2008, 111:776-784.
20. Tyybakinoja A., Elonen E., Piippo K., Porkka K., Knuutila S. Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia. Leukemia 2007, 21:571-574.
21. Struski S., Helias C., Gervais C., Audhuy B., Zamfir A., Herbrecht R., et al. 13q deletions in B-cell lymphoproliferative disorders: frequent association with translocation. Cancer Genet Cytogenet 2007, 174:151-160.
22. Stirewalt D.L., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003, 3:650-665.
23. Bonci D., Coppola V., Musumeci M., Addario A., Giuffrida R., Memeo L., et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008, 14:1271-1277.
24. Calin G.A., Cimmino A., Fabbri M., Ferracin M., Wojcik S.E., Shimizu M., et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008, 105:5166-5171.
25. Feuk L., Marshall C.R., Wintle R.F., Scherer S.W. Structural variants: changing the landscape of chromosomes and design of disease studies. Hum Mol Genet 2006, 15:R57-66. Spec No. 1.
26. Sawada A., Takihara Y., Kim J.Y., Matsuda-Hashii Y., Tokimasa S., Fujisaki H., et al. A congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humans. J Clin Invest 2003, 112:1707-1713.
27. Radich J.P., Dai H., Mao M., Oehler V., Schelter J., Druker B., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006, 103:2794-2799.